Bristol Myers Squibb
FDA Approves First New Drug for Schizophrenia in Decades
Bristol Myers Squibb (BMS) recently received U.S. Food & Drug Administration approval for COBENFY, a new twice-a-day oral medication for the ...
Updated July 21, 2022
BMS Aims to Boost Disability Diversity in Clinical Trials
Published May 2, 2022
BMS Wins FDA Approval for Drug to Treat Rare Form of Cardiac Disease
Updated February 10, 2022
BMS Awards $8 Million in Health Equity Grants to Improve Access to Care
Published October 4, 2021
When Circuitous Paths Lead to High-Tech Careers in STEM
Published September 30, 2021
BMS ‘Coast 2 Coast Ride 4 Cancer’ Raises $1.6 Million
Published October 5, 2020
Bristol Myers Squibb Explains Unique, Employee-led Volunteer Efforts
Read More
Personalize Your Experience.
Get started customizing today!
Become a Member Already a NJBIA member? Sign In
Employment & Labor Law
Economic Development
Energy & Environmental Quality
Taxation & Economic Development
Government Affairs
Health Affairs
Law
Education & Workforce Development
